Danaher Reports Third Quarter 2026 Results

Danaher Corporation (DHR) reported Q3 2026 earnings of $1.2B, or $1.71 per share, up 34.5% YoY. Revenue rose 8.5% to $6.6B. Non-GAAP adjusted EPS grew 11.5% to $2.11. The company raised full-year adjusted EPS guidance to $8.57-$8.62. Danaher expects Q4 core revenue growth of 3.0% YoY, excluding respiratory revenue.

Original reporting
Published Oct 21, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DHR
Bullish
high confidence
Mentioned
$DHR
Relevance
9/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$DHRBullishHigh
01

Why it matters

The earnings beat and raised guidance suggest continued momentum, likely supporting short-term price gains.

02

Market read

First report of Danaher's Q3 earnings and guidance, a primary disclosure for a large-cap stock.

03

What to watch

Potential headwinds from foreign currency impacts and upcoming acquisition integration costs.

Relevance 9/10Novelty 9/10Timing: immediate release today

Background

Danaher is a diversified life sciences and diagnostics company that regularly reports quarterly results.

Company-level read

Ticker impact

$DHRBullishHigh confidence
Context

Danaher reported Q3 2026 earnings with 34.5% EPS growth and raised full-year guidance to $8.57-$8.62 per share.

Expected impact

likely upward pressure as investors price in stronger earnings and raised guidance

Evidence & confidence

Revenue and earnings beat expectations; guidance increase signals sustained growth, prompting buying interest.

Market effects

Life sciences and diagnostics sector may see broader optimism from Danaher's strong performance.

U.S. markets could see a modest boost in healthcare indices.

Limited to investors tracking large-cap biotech and diagnostics firms.

Counterpoint

If the market has already priced in a strong quarter, the upside may be limited.

Key entities

  • Julie Sawyer Montgomery

    President and CEO of Danaher, provided commentary on results.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.